Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
KLAC$130.53-19.12(-12.78%)KLA Declares Regular Cash Dividend4:30:14 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:06 PM ETMU$665.03-130.43(-16.40%)Micron Announces Board of Directors Retirement4:30:00 PM ETKO$95.78-0.10(-0.10%)DRIVX Moves Toward Final Presale Stage, Unveils Fleet Expansion and Transparent Vesting Strategy4:19:08 PM ETCRWD$218.60-22.38(-9.29%)Why CrowdStrike and cybersecurity stocks got crunched in Thursday's rout4:12:00 PM ETNVDA$182.50-17.79(-8.88%)Nvidia's Huang is asked to brief Congress on reported Chinese spy relationship4:09:56 PM ETLRCX$191.05-30.23(-13.66%)Lam Research Corporation Announces $25 Billion Share Repurchase Authorization and Declares Quarterly Dividend4:05:00 PM ETSKHY$124.32-18.76(-13.11%)Why SK Hynix Plunged Today4:01:39 PM ETNVDA$182.50-17.79(-8.88%)Is Nvidia Still a Millionaire-Maker Stock?3:51:00 PM ETTSLA$341.91-43.27(-11.23%)SpaceX and Tesla Stock Plunges Have Wiped About $450 Billion in Value Since the Midterms. Is It Time to Buy?3:43:35 PM ETGOOGL$280.14-8.89(-3.08%)Google plans $17 billion Wyoming data center amid rising threats of curbs3:43:13 PM ETNOW$101.21-7.70(-7.07%)Arista Networks vs. ServiceNow: Which Technology Stock Is a Better Buy for 2027?3:43:02 PM ETGOOGL$280.14-8.89(-3.08%)BREAKINGVIEWS-Global muscle will sift puny data center providers3:30:09 PM ETAMD$408.18-80.51(-16.47%)Is AMD Stock a Buy as AI Revenue Soars?3:19:00 PM ETGEV$770.56-61.95(-7.44%)GE Vernova vs. NextEra Energy: Which Industrials Stock Is a Better Buy for 2027?3:17:11 PM ETBRK-A$857,487.54-9,063.79(-1.05%)Berkshire Hathaway Reports Nov. 7 With Its Stock at a Record. Its Cash Pile Is the Number to Watch.3:17:02 PM ETC$118.48+0.68(+0.58%)UPDATE 10-Brent crude jumps, settles up over $3 after tanker attacks3:15:37 PM ETCLX$99.10-0.10(-0.10%)Global Surface Disinfectant Market to Hit US$ 7.5 Bn by 2031, Registering at 7.4% CAGR: Wissen Research3:14:00 PM ETTM$218.30+18.94(+9.50%)ERI’s John Shegerian Describes the Current State of Rare Earth Mineral Recovery at World Remanufacturing Summit in Tokyo3:09:00 PM ETMRVL$135.35-24.56(-15.36%)Marvell Just Dropped 49% in a Month: Is MRVL Stock Hopeless or Ready for a Rebound?3:03:21 PM ETSPCX$123.50-12.33(-9.08%)Bull v. Bear: SPCX Faces Uncertainty as Midterm Results Pressure TSLA Merger3:00:38 PM ETINTC$52.09-6.19(-10.62%)Intel Shares Rise 6% To Intraday High After Key Trading Signal3:00:27 PM ETAMD$408.18-80.51(-16.47%)Advanced Micro Devices vs. Taiwan Semiconductor Manufacturing: The AI Sell-Off Is Exposing a Critical Difference Investors Shouldn't Ignore for 20273:00:02 PM ETHSY$177.43+2.93(+1.68%)Hershey vs. Coca-Cola: Which Consumer Goods Stock Is a Better Buy for 2027?2:51:29 PM ET

SANA · NASDAQ

Sana Biotechnology, Inc.

$2.48 -0.08 (-3.13%)

Company overview

Sana Biotechnology, Inc. is a biotechnology company focused on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders. Its product candidates include SG295 and SG242, which target CD19+ cancer cells such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$742M
Employees
194
Headquarters
Seattle, WA
Website
sana.com
CEO
Steven D. Harr
Listed
February 4, 2021
P/E
-2.67
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$2.4M
Operating income
-$238M
EBITDA
-$180M
Net income
-$242M
EPS
-$0.93
Total assets
$374M
Total debt
$75.3M
Earnings yield
-37.50%

Price chart

2.142.683.223.764.29
SANA 1D NASDAQ O2.55H2.62L2.46C2.56+0.12 (+4.92%)Vol2.64M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
SANASana Biotechnology, Inc. Stock news BRIEF-Sana Biotechnology Q3 Adjusted EPS USD -0.14 Vs. IBES Estimate USD -0.15 Reuters
SANASana Biotechnology, Inc. Press release Sana Biotechnology Reports Third Quarter 2026 Financial Results and Business Updates GlobeNewswire
SANASana Biotechnology, Inc. Press release Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction PR Newswire
SANASana Biotechnology, Inc. Stock news Sana Biotechnology: A Shot At Diabetes Seeking Alpha
SANASana Biotechnology, Inc. Stock news Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Seeking Alpha
SANASana Biotechnology, Inc. Stock news Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Seeking Alpha
SANASana Biotechnology, Inc. Stock news Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Seeking Alpha
SANASana Biotechnology, Inc. Press release Replacing Insulin Cells Works. Keeping The Cells Alive Is GlobeNewswire
SANASana Biotechnology, Inc. Press release Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire
SANASana Biotechnology, Inc. Press release Sana Biotechnology to Present at September 2026 Investor Conferences GlobeNewswire
SANASana Biotechnology, Inc. Stock news 3 Promising Genomics Stocks to Add to Your Portfolio in 2026 Zacks Investment Research
SANASana Biotechnology, Inc. Stock news Sana (SANA) Upgraded to Buy: Here's What You Should Know Zacks Investment Research
SANASana Biotechnology, Inc. Press release Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1. GlobeNewswire
SANASana Biotechnology, Inc. Press release Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 GlobeNewswire
SANASana Biotechnology, Inc. Press release Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PRNewsWire
SANASana Biotechnology, Inc. Press release Sana Biotechnology to Present at June 2026 Investor Conferences GlobeNewswire
SANASana Biotechnology, Inc. Press release Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility GlobeNewswire
SANASana Biotechnology, Inc. Stock news Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript Seeking Alpha
SANASana Biotechnology, Inc. Press release Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs GlobeNewswire
SANASana Biotechnology, Inc. Press release Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates GlobeNewswire
See more
FAQ

Questions about Sana Biotechnology, Inc.

What does Sana Biotechnology, Inc. do?
Sana Biotechnology, Inc. is a biotechnology company focused on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, and genetic disorders. Its product candidates include SG295 and SG242, which target CD19+ cancer cells such as non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency.
What is SANA's market cap?
Sana Biotechnology, Inc. (SANA) is a listed stock with a live quote. The latest market cap on this page is $742M.
Where is Sana Biotechnology, Inc. headquartered?
Sana Biotechnology, Inc. is headquartered in Seattle, WA.
How do I get SANA news from the API?
Call GET /v1/news?tickers=SANA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does SANA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for SANA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the SANA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs